StoxSai Life Sciences vs Global Health: share price & financials comparison
NSE: SAILIFE vs MEDANTA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sai Life Sciences vs Global Health at a glance
Sai Life Sciences (SAILIFE) has a market capitalisation of ₹37,919 Cr, against ₹37,281 Cr for Global Health (MEDANTA). Over the past year Sai Life Sciences has returned +94.7%, compared with +0.9% for Global Health. On valuation, Global Health trades at a lower P/E of 93.7 versus 187.2. Global Health earns a higher return on equity (9.2% vs 7.5%). Sai Life Sciences comes out ahead on profitability, momentum and technicals. Global Health comes out ahead on size, valuation, growth and financial health. Across the scored metrics below, Sai Life Sciences leads on 6 and Global Health on 6. On StoxGud's 10-point checklist, Sai Life Sciences scores 6/10 and Global Health scores 6/10.
| Metric | Sai Life Sciences | Global Health |
|---|---|---|
| Size | ||
| Market cap | ₹37,919 Cr | ₹37,281 Cr |
| Revenue (latest FY) | ₹2,192 Cr | ₹4,410 Cr |
| Net profit (latest FY) | ₹349 Cr | ₹556 Cr |
| Valuation | ||
| P/E | 187.2 | 93.7 |
| P/B | 14.11 | 8.62 |
| Dividend yield | — | 0.04% |
| Profitability | ||
| Return on equity | 7.5% | 9.2% |
| Net profit margin | 8.5% | 7.9% |
| Operating margin | 29.5% | 22.1% |
| Growth | ||
| Revenue growth (YoY) | +22.5% | +33.6% |
| Net profit growth (YoY) | — | -100.0% |
| Revenue CAGR (multi-year) | — | +17.9% |
| Financial health | ||
| Debt to equity | 0.17 | 0.16 |
| Momentum | ||
| 1-month return | +14.3% | +7.2% |
| 1-year return | +94.7% | +0.9% |
| 3-year CAGR | — | +18.3% |
| Distance from 52W high | +0.0% | -8.0% |
| Technicals | ||
| RSI (14) | 93 | 71 |
| Price vs 200-day avg | +47.1% | +11.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sai Life Sciences | Global Health |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sai Life Sciences or Global Health?
Sai Life Sciences has a market cap of ₹37,919 Cr and Global Health has a market cap of ₹37,281 Cr as of 06 Nov 2026.
Which has a lower P/E, Sai Life Sciences or Global Health?
Global Health has the lower P/E: Sai Life Sciences trades at 187.2 and Global Health at 93.7.
Which gave better returns in the last year, Sai Life Sciences or Global Health?
Sai Life Sciences did better: Sai Life Sciences returned +94.7% and Global Health returned +0.9% over one year.
Is Sai Life Sciences or Global Health a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Sai Life Sciences scores 6/10 and Global Health scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.